B052：美国胰腺癌患者血栓栓塞相关死亡率趋势：CDC WONDER分析（1999-2023）

IF 16.6 1区医学 Q1 ONCOLOGY

Cancer research Pub Date : 2025-09-28 DOI:10.1158/1538-7445.pancreatic25-b052

Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk

{"title":"B052：美国胰腺癌患者血栓栓塞相关死亡率趋势：CDC WONDER分析（1999-2023）","authors":"Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk","doi":"10.1158/1538-7445.pancreatic25-b052","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic cancer and thromboembolism frequently coexist, posing significant challenges in clinical management. The interplay between these conditions can exacerbate hemodynamic instability and influence treatment outcomes. This study aims to assess or evaluate the impact of thromboembolism related mortalities among patients with pancreatic cancer. Methods: We analyzed adults aged &gt;25 years death certificates from the CDC-WONDER database with pancreatic cancer (ICD-10 codes: C25) and thromboembolism (ICD-10 codes: I26, I80, and I82) from 1999-2023. Age-adjusted mortality rates (AAMR) per 100,000 were calculated, and trends were analyzed by gender, race, region and metropolitan status. Join-point regression was used to calculate annual percentage changes (APC) with 95 % confidence intervals (CI). Results: A total of 24,870 deaths were attributed to pancreatic cancer and thromboembolism related mortalities in individuals from 1999 to 2023. The AAMR increased from 0.31 in 1999 to 0.42 in 2011 (APC: 2.7; 95% CI: 1.91-3.5), then decreased to 0.4 in 2015 (APC: -1.34; 95% CI: -6.77 to 4.40), and ultimately increased to 0.65 in 2023 (APC: 7.39; 95% CI: 6.0-8.81) with an overall AAPC (3.55; 95% CI: 2.48-4.62). In terms of gender, both sexes show increment with higher AAMRs (1999-2023) in males from 0.35 to 0.76 (AAPC: 3.4; 95% CI: 2.84-3.97) compared to females from 0.27 to 0.58 (AAPC: 3.61; 95% CI: 2.02-5.22). From 1999 to 2023, Non-Hispanic (NH) Black or African American displayed the highest AAMR (0.47-1.09), followed by NH White (0.29-0.64), and Hispanic or Latino (0.21-0.45). Geographically, The AAMR for the Northeast ranged from 0.35 in 1999 to 0.67 in 2023, followed by the Midwest (0.31-0.67), the South (0.3-0.67), and the West (0.29-0.6). Metropolitan areas had the highest overall AAMR (0.4) while Nonmetropolitan areas had the lowest (0.38). Conclusion: Mortalities related to pancreatic cancer and thromboembolism have increased, with highest rates among males, Black population, and those in Northeastern and urban U.S., requiring targeted, equitable public health strategies. Citation Format: Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk. Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr B052.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"17 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract B052: Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023)\",\"authors\":\"Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk\",\"doi\":\"10.1158/1538-7445.pancreatic25-b052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Pancreatic cancer and thromboembolism frequently coexist, posing significant challenges in clinical management. The interplay between these conditions can exacerbate hemodynamic instability and influence treatment outcomes. This study aims to assess or evaluate the impact of thromboembolism related mortalities among patients with pancreatic cancer. Methods: We analyzed adults aged &gt;25 years death certificates from the CDC-WONDER database with pancreatic cancer (ICD-10 codes: C25) and thromboembolism (ICD-10 codes: I26, I80, and I82) from 1999-2023. Age-adjusted mortality rates (AAMR) per 100,000 were calculated, and trends were analyzed by gender, race, region and metropolitan status. Join-point regression was used to calculate annual percentage changes (APC) with 95 % confidence intervals (CI). Results: A total of 24,870 deaths were attributed to pancreatic cancer and thromboembolism related mortalities in individuals from 1999 to 2023. The AAMR increased from 0.31 in 1999 to 0.42 in 2011 (APC: 2.7; 95% CI: 1.91-3.5), then decreased to 0.4 in 2015 (APC: -1.34; 95% CI: -6.77 to 4.40), and ultimately increased to 0.65 in 2023 (APC: 7.39; 95% CI: 6.0-8.81) with an overall AAPC (3.55; 95% CI: 2.48-4.62). In terms of gender, both sexes show increment with higher AAMRs (1999-2023) in males from 0.35 to 0.76 (AAPC: 3.4; 95% CI: 2.84-3.97) compared to females from 0.27 to 0.58 (AAPC: 3.61; 95% CI: 2.02-5.22). From 1999 to 2023, Non-Hispanic (NH) Black or African American displayed the highest AAMR (0.47-1.09), followed by NH White (0.29-0.64), and Hispanic or Latino (0.21-0.45). Geographically, The AAMR for the Northeast ranged from 0.35 in 1999 to 0.67 in 2023, followed by the Midwest (0.31-0.67), the South (0.3-0.67), and the West (0.29-0.6). Metropolitan areas had the highest overall AAMR (0.4) while Nonmetropolitan areas had the lowest (0.38). Conclusion: Mortalities related to pancreatic cancer and thromboembolism have increased, with highest rates among males, Black population, and those in Northeastern and urban U.S., requiring targeted, equitable public health strategies. Citation Format: Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk. Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr B052.\",\"PeriodicalId\":9441,\"journal\":{\"name\":\"Cancer research\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2025-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.pancreatic25-b052\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1538-7445.pancreatic25-b052","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：胰腺癌和血栓栓塞经常共存，对临床管理提出了重大挑战。这些情况之间的相互作用可加剧血流动力学不稳定并影响治疗结果。本研究旨在评估或评价胰腺癌患者血栓栓塞相关死亡率的影响。方法：我们分析了年龄为& &；gt；来自CDC-WONDER数据库的1999-2023年间25年的胰腺癌（ICD-10代码：C25）和血栓栓塞（ICD-10代码：I26、I80和I82）死亡证明。计算了每10万人的年龄调整死亡率（AAMR），并按性别、种族、地区和大都市状况分析了趋势。采用联结点回归计算年百分比变化（APC），置信区间为95%。结果：从1999年到2023年，共有24,870人死于胰腺癌和血栓栓塞相关的死亡。AAMR从1999年的0.31上升到2011年的0.42 (APC: 2.7, 95% CI: 1.91 ~ 3.5)， 2015年下降到0.4 （APC: -1.34, 95% CI: -6.77 ~ 4.40)，最终在2023年上升到0.65 (APC: 7.39, 95% CI: 6.0 ~ 8.81)，总体AAPC为3.55,95% CI: 2.48 ~ 4.62）。在性别方面，两性均呈增加趋势，男性的aamr从0.35增加到0.76 (AAPC: 3.4, 95% CI: 2.84-3.97)，女性的AAPC从0.27增加到0.58 （AAPC: 3.61, 95% CI: 2.02-5.22）。1999 - 2023年，非西班牙裔（NH）黑人或非洲裔美国人的AAMR最高（0.47-1.09），其次是NH白人（0.29-0.64）和西班牙裔或拉丁裔（0.21-0.45）。从地理上看，东北部的AAMR从1999年的0.35到2023年的0.67不等，其次是中西部（0.31-0.67）、南部（0.3-0.67）和西部（0.29-0.6）。首都圈的AAMR最高（0.4），非首都圈最低（0.38）。结论：胰腺癌和血栓栓塞相关的死亡率已经增加，其中男性、黑人以及美国东北部和城市的死亡率最高，需要有针对性的、公平的公共卫生策略。引文格式：Sravani Bhavanam， Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul。Mulk。美国胰腺癌患者血栓栓塞相关死亡率趋势：CDC WONDER分析（1999-2023）[摘要]。摘自：AACR癌症研究特别会议论文集：胰腺癌研究进展-新兴科学驱动变革解决方案；波士顿;2025年9月28日至10月1日；波士顿,MA。费城（PA）： AACR；癌症研究2025；85(18_Suppl_3): nr B052。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Abstract B052: Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023)

Background: Pancreatic cancer and thromboembolism frequently coexist, posing significant challenges in clinical management. The interplay between these conditions can exacerbate hemodynamic instability and influence treatment outcomes. This study aims to assess or evaluate the impact of thromboembolism related mortalities among patients with pancreatic cancer. Methods: We analyzed adults aged >25 years death certificates from the CDC-WONDER database with pancreatic cancer (ICD-10 codes: C25) and thromboembolism (ICD-10 codes: I26, I80, and I82) from 1999-2023. Age-adjusted mortality rates (AAMR) per 100,000 were calculated, and trends were analyzed by gender, race, region and metropolitan status. Join-point regression was used to calculate annual percentage changes (APC) with 95 % confidence intervals (CI). Results: A total of 24,870 deaths were attributed to pancreatic cancer and thromboembolism related mortalities in individuals from 1999 to 2023. The AAMR increased from 0.31 in 1999 to 0.42 in 2011 (APC: 2.7; 95% CI: 1.91-3.5), then decreased to 0.4 in 2015 (APC: -1.34; 95% CI: -6.77 to 4.40), and ultimately increased to 0.65 in 2023 (APC: 7.39; 95% CI: 6.0-8.81) with an overall AAPC (3.55; 95% CI: 2.48-4.62). In terms of gender, both sexes show increment with higher AAMRs (1999-2023) in males from 0.35 to 0.76 (AAPC: 3.4; 95% CI: 2.84-3.97) compared to females from 0.27 to 0.58 (AAPC: 3.61; 95% CI: 2.02-5.22). From 1999 to 2023, Non-Hispanic (NH) Black or African American displayed the highest AAMR (0.47-1.09), followed by NH White (0.29-0.64), and Hispanic or Latino (0.21-0.45). Geographically, The AAMR for the Northeast ranged from 0.35 in 1999 to 0.67 in 2023, followed by the Midwest (0.31-0.67), the South (0.3-0.67), and the West (0.29-0.6). Metropolitan areas had the highest overall AAMR (0.4) while Nonmetropolitan areas had the lowest (0.38). Conclusion: Mortalities related to pancreatic cancer and thromboembolism have increased, with highest rates among males, Black population, and those in Northeastern and urban U.S., requiring targeted, equitable public health strategies. Citation Format: Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk. Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023) [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3): nr B052.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer research 医学-肿瘤学

CiteScore

16.10

自引率

0.90%

发文量

7677

审稿时长

2.5 months

期刊介绍： Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research. With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445. Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.